The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

U.K. scientists have used mass spectrometry to look in detail at how adeno-associated viruses (AAVs) release their genetic cargo when infecting host cells. The team, from the University of Leeds, ...

HIV hijacks SRRM2 to enlarge nuclear speckles, stabilizing CPSF6 puncta and promoting efficient viral replication.

Over the last three decades, scientists have devised molecular shuttles that slip enzymes, antibodies, and other molecules into the central nervous system (CNS) by attaching them to the transferrin ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...